Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

Rhea-AI Summary

Psyence BioMed (Nasdaq: PBM) exported GMP-manufactured natural psilocybin NPX-5 (1 mg and 5 mg capsules) to Australia to supply its ongoing Phase IIb trial for Adjustment Disorder in palliative oncology.

The multi-center, double-blind trial is enrolling 87 participants across Australian sites including Melbourne and Perth; patient dosing began in late 2025 and newly enrolled patients will receive NPX-5. PsyLabs manufactured the product and holds a 49.98% equity stake in Psyence BioMed.

Positive

• GMP export completed of NPX-5 to Australia
• Phase IIb trial actively enrolling 87 participants
• Vertical integration across cultivation, extraction, manufacturing, QA
• Operational readiness demonstrated for global supply chain

Negative

• PsyLabs 49.98% stake presents potential related-party considerations
• Limited trial size of 87 participants may restrict statistical power

Key Figures

NPX-5 dose: 1 mg NPX-5 dose: 5 mg Planned enrollment: 87 participants +2 more

5 metrics

NPX-5 dose 1 mg Capsule strength for GMP-manufactured psilocybin product

NPX-5 dose 5 mg Capsule strength for GMP-manufactured psilocybin product

Planned enrollment 87 participants Phase IIb trial in Australian palliative cancer patients

Trial phase Phase IIb Natural psilocybin trial for Adjustment Disorder in cancer

PsyLabs equity stake 49.98% PsyLabs’ ownership interest in Psyence BioMed

Market Reality Check

Price: $2.56 Vol: Volume 21,790 vs 20-day a...

low vol

$2.56 Last Close

Volume Volume 21,790 vs 20-day average 534,837 (relative volume 0.04), indicating limited pre-news activity. low

Technical Shares at $2.56, trading below 200-day MA of $19.33, reflecting a prolonged downtrend before this update.

Peers on Argus

PBM was up 0.79% pre-news with light volume, while only one scanned biotech peer...

1 Up

PBM was up 0.79% pre-news with light volume, while only one scanned biotech peer (PPBT) showed modest upside momentum and no same-direction cluster across key peers, pointing to stock-specific drivers.

Previous Clinical trial Reports

5 past events · Latest: Dec 19 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 19	Ethics approval update	Positive	-31.5%	Ethics approval to use PsyLabs’ NPX5 in the Phase IIb trial.
May 27	CRO agreement	Positive	+3.9%	Finalized Southern Star CRO agreement to manage Phase IIb trial.
Apr 08	LOI for CRO	Positive	+0.6%	LOI with Southern Star Research to expand Australian Phase IIb trial.
Mar 31	Corporate clinical update	Positive	-4.5%	Corporate update on Phase IIb trial, IP licensing, and new trials.
Dec 17	Trial progress report	Positive	-5.4%	Progress on Phase IIb trial with site activations and recruitment prep.

Pattern Detected

Clinical trial updates have generally been positive in tone but often met with negative next-day price reactions.

Recent Company History

Over the past year, PBM has issued multiple updates on the same Phase IIb trial in Australia, including site activations, CRO partnerships, and ethics approval for using PsyLabs’ NPX5 product. These releases highlighted enrollment targets of 87 participants, palliative oncology focus, and a vertically integrated supply model with PsyLabs. Despite advancing the program and reinforcing manufacturing and IP access, several of these clinically positive milestones were followed by negative one-day price moves, underscoring weak investor risk appetite ahead of efficacy data.

Historical Comparison

-7.4% avg move · Past clinical-trial updates (5 events) averaged a -7.4% next-day move, suggesting that operational m...

clinical trial

-7.4%

Average Historical Move clinical trial

Past clinical-trial updates (5 events) averaged a -7.4% next-day move, suggesting that operational milestones like today’s export step have not consistently attracted bullish trading interest.

Clinical updates trace a steady build-out of the same Phase IIb program: initial site activations, CRO transition and expansion, ethics approval for NPX5, and now GMP-manufactured NPX-5 export to support active dosing in the Australian palliative oncology trial.

Market Pulse Summary

This announcement advances PBM’s Phase IIb program by confirming GMP manufacturing, export of NPX-5 ...

Analysis

This announcement advances PBM’s Phase IIb program by confirming GMP manufacturing, export of NPX-5 capsules, and use of the product in an 87-patient Australian palliative oncology trial. It reinforces the vertically integrated relationship with PsyLabs, which holds a 49.98% stake and operates the GMP facility. Historically, similar clinical updates have produced uneven trading responses, so investors may focus on trial enrollment progress, safety data, and eventual efficacy readouts as key future catalysts.

Key Terms

gmp-compliant, psilocybin, ibogaine, phase iib, +4 more

8 terms

gmp-compliant technical

"successful export of fully GMP-compliant manufactured psilocybin product NPX-5"

Good Manufacturing Practice (GMP) compliant means a maker follows established, inspectable rules for producing medicines, medical devices, or other regulated products so each batch is safe, consistent and of expected quality. For investors, GMP compliance lowers the chance of regulatory shutdowns, recalls or delays and increases the likelihood products can be sold; think of it as a verified recipe and checklist that keeps a factory from making faulty batches.

psilocybin medical

"advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs"

A naturally occurring psychedelic compound found in certain mushrooms that alters perception, mood and consciousness; when taken the body converts it into an active substance that produces short-term hallucinogenic effects. Investors watch psilocybin because researchers and drug developers are exploring it as a potential treatment for depression, PTSD and other mental health conditions, so clinical trial results, regulatory decisions and changing stigma can create large commercial opportunities or risks—think of it as a new drug category whose approval pathway can drive big swings in company value.

ibogaine medical

"advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs"

A naturally derived psychoactive compound used experimentally to treat substance use disorders and certain mental health conditions; it acts on the brain to reduce cravings and withdrawal symptoms. Investors care because a successful, approved therapy could open a new treatment market, while safety concerns, mixed clinical evidence, and strict regulatory oversight create high development risk—think of it as an experimental key that may unlock value but must pass several safety locks first.

phase iib medical

"ongoing Phase IIb clinical trial in Australia – a double-blind, randomized"

Phase IIb is a mid-stage clinical trial that tests whether an experimental treatment works and what dose is best by studying it in a larger group of patients than early tests. For investors, Phase IIb results are important because they substantially reduce uncertainty about a drug’s effectiveness and safety, and positive or negative outcomes often drive company valuation, partnership interest, and the likelihood of advancing to the large, costly Phase III trials.

double-blind medical

"ongoing Phase IIb clinical trial in Australia – a double-blind, randomized"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

randomized medical

"ongoing Phase IIb clinical trial in Australia – a double-blind, randomized"

Randomized means participants or units in a study are assigned to different groups by chance rather than by choice, like flipping a coin to decide who gets a new treatment and who gets a comparison. For investors, randomized designs matter because they reduce bias and make results more trustworthy, so outcomes from randomized studies carry more weight when assessing regulatory approval, commercial prospects, and the risk that trial results will change a company’s valuation.

palliative care medical

"Adjustment Disorder in patients with cancer in a palliative care context"

Palliative care is medical and supportive treatment focused on easing symptoms, pain and emotional stress for people with serious illness, rather than trying to cure the underlying disease. For investors it matters because demand for palliative services, drugs and devices, staffing and facility types affects health-care spending, reimbursement patterns and market growth—think of it as the comfort and support side of medicine that creates its own steady stream of products and services.

vertically integrated technical

"validates the operational readiness of our vertically integrated model"

Vertically integrated describes a company that owns and controls multiple steps in making and selling its products or services — for example sourcing raw materials, manufacturing, and distribution. Like a bakery that grows its own wheat, mills the flour, bakes the bread and runs the shops, this setup can lower costs, improve quality and speed to market and protect profit margins, but it also requires more capital and can reduce flexibility.

AI-generated analysis. Not financial advice.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the successful export of fully GMP-compliant manufactured psilocybin product NPX-5 (1mg and 5mg capsules) to Australia. The product was manufactured at the Psyence Labs Ltd. (“PsyLabs”) GMP-controlled production facility, supporting pharmaceutical-grade psychedelic development.

The shipment represents an operational achievement for both Psyence BioMed and PsyLabs, reinforcing their shared commitment to establishing a regulated global supply chain for nature-derived psychedelic therapeutics.

The exported NPX-5 product will now be used in Psyence BioMed’s ongoing Phase IIb clinical trial in Australia – a double-blind, randomized, low-dose comparator-controlled, multi-center study evaluating natural psilocybin for the treatment of Adjustment Disorder in patients with cancer in a palliative care context.

The trial is enrolling 87 participants across multiple Australian sites, including Melbourne and Perth. Psyence BioMed is currently the only company conducting a Phase IIb clinical trial using natural psilocybin to study Adjustment Disorder in a palliative oncology population. Patient dosing is underway, with initial participants having been dosed in late 2025, and all newly enrolled patients will be dosed with NPX-5.

“This export demonstrates more than regulatory clearance – it validates the operational readiness of our vertically integrated model,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. “The successful manufacture and export of GMP-compliant natural psilocybin at this stage of clinical development demonstrates that we are not simply participating in this sector – we are helping define its standards. Operational discipline, supply control, and product excellence are foundational to our platform.”

Clinical Significance

The Phase IIb trial focuses on Adjustment Disorder, an excessive and sometimes debilitating psychological response to a significant life stressor – in this case, advanced cancer. The study aims to evaluate the efficacy, safety, and durability of a psycho-therapeutic approach utilizing nature-derived psilocybin to reduce anxiety and depressive symptoms in this vulnerable patient population.

As a regulated, nature-derived formulation rather than a synthetic analogue, Psyence BioMed’s approach represents a differentiated pathway within psychedelic therapeutics – integrating pharmaceutical-grade manufacturing with clinical rigor in palliative mental health care.

“Our team executed this export with efficiency and strict adherence to GMP standards because patient safety is paramount,” said Tony Budden, CEO of PsyLabs. “Every capsule supplied to this trial has been produced under rigorous quality controls to help ensure a safe, consistent, and reliable experience for patients participating in this important study.”

Manufacturing & Global Supply Chain Leadership

PsyLabs operates a GMP-compliant production and analytical facility capable of manufacturing pharmaceutical-grade natural psilocybin and ethically sourced ibogaine at scale. The successful export of NPX-5 capsules to Australia demonstrates:

• Full GMP compliance.
• International regulatory authorization for shipment.
• Operational global supply chain capability.
• Vertical integration across cultivation, extraction, manufacturing, and quality assurance.

This development further strengthens the strategic alignment between Psyence BioMed and PsyLabs as they build a scalable, compliant, and resilient global infrastructure for nature-derived psychedelic medicines. PsyLabs holds a 49.98% equity stake in the Company and Certain members of the Company’s management are affiliates of PsyLabs and have financial interests in PsyLabs.

“As the psychedelic sector matures, infrastructure and supply certainty will differentiate sustainable pharmaceutical platforms,” added Aufrichtig. “This shipment marks meaningful progress in advancing our strategy and demonstrates our ongoing efforts to operate in a disciplined and globally coordinated manner.”

Learn more at www.psyencebiomed.com and on LinkedIn.

Contact Information for Psyence Biomedical Ltd. 
Email: ir@psyencebiomed.com   
Media Inquiries: media@psyencebiomed.com  
General Information: info@psyencebiomed.com  

Investor Contact: 
Michael Kydd 
Investor Relations Advisor 
michael@psyencebiomed.com  

Forward Looking Statements 

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding future financial and operating results; the progress, timing, enrollment, dosing, data readouts and regulatory status of the Company’s Phase IIb clinical trial; the manufacture, export and supply of NPX-5; the expansion of PsyLabs’ manufacturing capabilities; the development of a regulated global supply chain; the Company’s vertically integrated business model; anticipated regulatory authorizations; market opportunity and demand for psychedelic-assisted therapies; and the Company’s plans, objectives, expectations and intentions with respect to future operations, products and services. Forward-looking statements are generally identified by words such as “will,” “may,” “expects,” “anticipates,” “believes,” “intends,” “plans,” “estimates,” “projects,” “continues,” “could,” “would,” or similar expressions.

Forward-looking statements in this communication are based on current assumptions and expectations, including, among others, assumptions that the Company’s clinical trial will proceed as currently anticipated; that patient enrollment, dosing and site expansion will occur on expected timelines; that required regulatory approvals, import/export authorizations and institutional consents will be maintained; that manufacturing operations will remain compliant with applicable GMP requirements; that product supply will not be disrupted; and that demand for psychedelic-assisted therapy will continue to develop. These assumptions may prove to be incorrect.

There can be no assurance that the Company’s clinical trial will be completed on its current timeline or at all, that regulatory approvals will be obtained or maintained, that manufacturing scale-up or international shipment of product will continue without interruption, or that the Company’s vertically integrated strategy will result in commercial success. There can be no assurance as to when a share consolidation will be implemented, if at all.

Numerous risks and uncertainties could cause actual results or performance to differ materially from those expressed or implied by forward-looking statements. These risks and uncertainties include, among others: (i) the Company’s ability to maintain compliance with Nasdaq’s continued listing standards; (ii) volatility in the Company’s share price; (iii) changes in applicable laws, regulations or regulatory interpretations in the United States, Australia or other jurisdictions; (iv) risks associated with clinical development, including delays in enrollment, dosing, data collection, analysis or regulatory review; (v) risks related to the manufacture, quality control, scale-up and continued GMP compliance of the Company’s product candidates; (vi) risks associated with international shipment, import/export controls and cross-border regulatory requirements; (vii) dependence on third-party manufacturers, suppliers, clinical sites and collaborators; (viii) competitive developments, including other companies pursuing similar indications or alternative therapeutic approaches; (ix) the uncertainty of clinical trial outcomes and the possibility that clinical results may not support regulatory approval or commercialization; and (x) general economic, capital markets and industry conditions. The foregoing list is not exhaustive.

You should carefully consider these risks and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025, as amended, and in other documents filed by Psyence BioMed from time to time with the SEC.

Actual results and future events could differ materially from those anticipated in forward-looking statements. Nothing in this communication should be regarded as a representation that any forward-looking statement will be achieved. Forward-looking statements speak only as of the date they are made, and except as required by applicable law, Psyence BioMed undertakes no obligation to update or revise them.

The Company does not make any medical, treatment or health benefit claims regarding its investigational product candidates. The U.S. Food and Drug Administration, Health Canada and other regulatory authorities have not approved psilocybin, psilocybin analogues or other psychedelic compounds for the treatment of Adjustment Disorder or other indications described herein. Any references to quality, consistency, efficacy or safety relate to investigational products that are currently being evaluated in clinical trials. The safety and efficacy of such product candidates have not been established, and there can be no assurance that ongoing or future clinical trials will demonstrate sufficient safety or efficacy to obtain regulatory approval. If the Company is unable to obtain required regulatory approvals or successfully commercialize its product candidates, its business, financial condition and results of operations may be materially adversely affected.

FAQ

What did Psyence BioMed (PBM) announce on March 3, 2026 regarding NPX-5?

They announced the successful export of GMP-manufactured NPX-5 to Australia to support a Phase IIb trial. According to the company, the shipment supplies a double-blind, randomized study evaluating natural psilocybin for Adjustment Disorder in palliative oncology and enables ongoing patient dosing.

What is NPX-5 and what doses did Psyence BioMed (PBM) export to Australia?

NPX-5 is a pharmaceutical-grade, nature-derived psilocybin formulation supplied in 1 mg and 5 mg capsules. According to the company, the product was manufactured under GMP at PsyLabs and exported to supply clinical dosing in the Phase IIb study.

How many patients and sites are involved in Psyence BioMed's (PBM) Phase IIb trial in Australia?

The Phase IIb study is enrolling 87 participants across multiple Australian sites, including Melbourne and Perth. According to the company, the multi-center trial uses a double-blind, randomized, low-dose comparator-controlled design focused on palliative oncology patients with Adjustment Disorder.

When did patient dosing begin and will newly enrolled patients receive NPX-5 in the PBM trial?

Patient dosing began in late 2025 and all newly enrolled patients will be dosed with NPX-5. According to the company, initial participants were already dosed and the exported GMP capsules will supply ongoing dosing in the trial.

What investor-related disclosure did Psyence BioMed (PBM) include about PsyLabs ownership?

PsyLabs holds a 49.98% equity stake in Psyence BioMed, creating related-party and governance relevance for investors. According to the company, certain management members are affiliates of PsyLabs and have financial interests in PsyLabs.